Cargando…
Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients
INTRODUCTION: Previous studies have demonstrated the superior efficacy of a novel aerosol foam formulation of fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064% (BD), compared with the ointment formulation. The aim of this study is to ascertain whether enhanced bioava...
Autores principales: | Lind, Marianne, Nielsen, Kim Troensegaard, Schefe, Line Hollesen, Nørremark, Kasper, Eriksson, André Huss, Norsgaard, Hanne, Pedersen, Brian Thoning, Petersson, Karsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972731/ https://www.ncbi.nlm.nih.gov/pubmed/27358072 http://dx.doi.org/10.1007/s13555-016-0125-6 |
Ejemplares similares
-
Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination
por: Jalili, Ahmad, et al.
Publicado: (2022) -
Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review
por: Patel, Nupur U, et al.
Publicado: (2017) -
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis
por: Queille-Roussel, Catherine, et al.
Publicado: (2016) -
Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review
por: Narbutt, Joanna, et al.
Publicado: (2021) -
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study
por: Koo, John, et al.
Publicado: (2016)